Related Experiment Video
Updated: Dec 9, 2025
08:42
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
3.9K
Transcatheter Tricuspid Valve Intervention: Coaptation Devices
Guillem Muntané-Carol1, Alberto Alperi1, Laurent Faroux1
1Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada.
Frontiers in Cardiovascular Medicine
|September 9, 2020
Summary
Transcatheter tricuspid valve intervention using coaptation devices offers a new treatment for severe tricuspid regurgitation. These devices show promising early and mid-term results for patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Severe tricuspid regurgitation (TR) poses significant clinical challenges.
- Transcatheter tricuspid valve intervention (TTVI) has emerged as a less invasive treatment option.
- Coaptation devices represent a key technology within TTVI.
Purpose of the Study:
- To review the clinical evidence for coaptation devices in TTVI.
- To describe the design and procedural aspects of these devices.
- To summarize early and mid-term patient outcomes.
Main Methods:
- Literature review of clinical studies on TTVI coaptation devices.
- Analysis of device designs, including leaflet plication and spacer mechanisms.
- Evaluation of reported procedural success and patient outcomes.
Main Results:
- Several coaptation devices, including MitraClip/TriClip, PASCAL, and FORMA, are available for TTVI.
- These devices aim to reduce TR by approximating or bridging valve leaflets.
- Early and mid-term data suggest promising efficacy and safety profiles.
Conclusions:
- Coaptation devices are a significant advancement in the management of severe TR via TTVI.
- Further research and long-term data are essential to fully establish their role.
- These devices offer a valuable alternative for patients unsuitable for surgery.
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
149
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
149
01:25Mitral Regurgitation III: Medical Management
166
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
166
01:25Aortic Regurgitation III: Medical Management
217
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
217